Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:25 PM
Ignite Modification Date:
2025-12-24 @ 9:25 PM
NCT ID:
NCT05554432
Eligibility Criteria:
Patients :
Inclusion Criteria:
* Provision of written informed consent to participate in the study
* Has been diagnosed with cancer
* Either currently receiving, or has received in the previous 12 months, one of the following:
* an anti-PD-1 or anti-PDL-1 agent as the sole immune checkpoint inhibitor treatment (at least three cycles)
* an anti-PD-1 or anti-PDL-1 agent in combination with an anti-CTLA-4 agent (at least one cycle)
* cytotoxic chemotherapy and an anti-PD-1 or anti-PDL-1 agent (at least three cycles)
* Aged ≥18 years
Exclusion Criteria:
* Has an additional primary cancer for which they are receiving systemic therapy
* Cognitive impairment which presents an obstacle to the completion of questionnaires or an interview
* Poor command of the locally dominant language, or an inability to read questions
* \[Phase 1b only\] Was interviewed for Phase 1a
Healthcare professionals :
Inclusion Criteria:
* Holds, or has held, a professional clinical position which involves working directly with cancer patients who are in receipt of immune checkpoint inhibitors
* Is a medical oncologist, nurse specialist (or equivalent), psychologist, or social worker
Exclusion Criteria:
• Has met the inclusion criteria for \<1 years
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05554432
Study Brief:
Protocol Section:
NCT05554432